Status:
RECRUITING
68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer
Lead Sponsor:
Peking University First Hospital
Conditions:
SCLC
SCLC, Extensive Stage
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study aims to investigate and evaluate the safety and performance of a novel probe, PFD3, for the diagnosis and assessment of patients with small cell lung cancer (SCLC).
Detailed Description
Small cell lung cancer (SCLC) constitutes approximately 15% of all lung cancers and is characterized by its aggressive biology, rapid growth, and early, widespread metastasis. It is highly lethal, wit...
Eligibility Criteria
Inclusion Criteria:
- Adults.
- Histologically confirmed small cell lung cancer (SCLC).
- At least one measurable lesion ≥1 cm in diameter (primary tumor, metastatic lesion, or involved lymph node) confirmed by standard imaging modalities.
- Laboratory tests (complete blood count and biochemical analysis) completed within 4 weeks prior to enrollment.
Exclusion Criteria:
- Pregnancy.
- Breastfeeding.
- Acute psychiatric disorders.
- Inability to undergo PET scanning (e.g., due to claustrophobia, weight limits, or other medical contraindications).
- Inability to complete the study procedures as anticipated.
- Prior therapy targeting DLL3.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2027
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT07508852
Start Date
June 1 2025
End Date
December 31 2027
Last Update
April 2 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking university first hospital nuclear medicine
Beijing, Beijing Municipality, China, 100034